Wanbury Limited

NSE WANBURY.NS

Wanbury Limited Gross Profit Margin for the year ending March 31, 2024: 46.29%

Wanbury Limited Gross Profit Margin is 46.29% for the year ending March 31, 2024, a 17.37% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • Wanbury Limited Gross Profit Margin for the year ending March 31, 2023 was 39.44%, a -0.65% change year over year.
  • Wanbury Limited Gross Profit Margin for the year ending March 31, 2022 was 39.70%, a -6.91% change year over year.
  • Wanbury Limited Gross Profit Margin for the year ending March 31, 2021 was 42.64%, a -7.94% change year over year.
  • Wanbury Limited Gross Profit Margin for the year ending March 31, 2020 was 46.32%, a 3.36% change year over year.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
Loading...
SV Wall Street
NSE: WANBURY.NS

Wanbury Limited

CEO Mr. Pradeep Patni
IPO Date Jan. 29, 2007
Location India
Headquarters BSEL Tech Park, B-Wing
Employees 1,491
Sector Healthcare
Industries
Description

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India. The company offers formulations for gynecology, orthopedics, heamatinics, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner purposes approximately under 70 brands. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas. Wanbury Limited also exports its products. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. The company was incorporated in 1988 and is headquartered in Navi Mumbai, India.

Similar companies

THEMISMED.NS

Themis Medicare Limited

USD 2.62

1.36%

VIMTALABS.NS

Vimta Labs Limited

USD 9.86

2.71%

VENUSREM.NS

Venus Remedies Limited

USD 3.47

1.60%

XPROINDIA.NS

Xpro India Limited

USD 14.57

1.32%

StockViz Staff

February 2, 2025

Any question? Send us an email